LifeSci Acquisition II Corp. LSAQ
Set alert
At close
- Open
- 8.83
- Prev close
- 9.01
- Mkt cap
- 90.20M
- Vol
- 41.67K
- Avg vol
- 36.60K
- EPS
- -0.056
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 8.42
- High
- 9.25
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 10.40
- Inst. own
- 77.32%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 9.91
- 200-d avg
- 10.05
- 1y target
- 0.00
News
3 years ago investorplace.com
Why Is Science 37 (SNCE) Stock Up 9% Today?
Science 37 (NASDAQ: SNCE ) stock is rising higher on Monday following news of inducement equity awards for its Metasite employees. According to a press release from Science 37, the awards were…
4 years ago seekingalpha.com
Science 37 Holdings, Inc. (SNCE) CEO David Coman on Q4 2021 Results - Earnings Call Transcript
Science 37 Holdings, Inc. (SNCE) CEO David Coman on Q4 2021 Results - Earnings Call Transcript
4 years ago seekingalpha.com
Science 37: Pioneering Decentralized Clinical Trials
Science 37 pioneered the concept of decentralized clinical trials. The Covid-19 pandemic drove more demand for DCTs.
5 years ago benzinga.com
'SPACs Attack' Recap: Looking Back At 5 SPAC Deals, Rumors And Top Headlines
Last week featured five announced SPAC deals and several rumors. The week also had earnings from several well-known former SPACs.
-
5 years ago benzinga.com
Stocks That Hit 52-Week Lows On Thursday
During Thursday's morning session, 92 stocks hit new 52-week lows.
-
5 years ago benzinga.com
Stocks That Hit 52-Week Highs On Wednesday
Before 10 a.m. ET on Wednesday, 285 companies set new 52-week highs.
5 years ago seekingalpha.com
U.S. IPO Weekly Recap: Breast Cancer Biotech Pops 158% In A 6-IPO Week
In a scramble to go public ahead of the holiday, six IPOs and 15 SPACs went public this past week led by breast cancer biotech Olema Pharmaceuticals, which soared 158% on its first day. New filings…
5 years ago globenewswire.com
LifeSci Acquisition II Corp. Announces Pricing of $75 Million Initial Public Offering
NEW YORK, Nov. 20, 2020 (GLOBE NEWSWIRE) -- LifeSci Acquisition II Corp. (NASDAQ: LSAQ), a blank check company targeting the biopharma sector, announced today that it priced its initial public…